The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As major pharmaceutical companies increasingly focus on rare diseases, Sanofi announced positive results for Nexviazyme in infantile Pompe disease. The Phase 3 trial met all endpoints, supporting the company's plans to file for a US label expansion in 2026.
This announcement follows earlier successes of Nexviazyme in late-onset Pompe disease, strengthening Sanofi's position in the rare genetic disease treatment market. According to market data, SNY shares closed at $43.43 on June 29, 2026, trading between $42.76 and $43.48. The stock showed no major move following the news.
Sign in to access this content
Sign InInvestors are now focused on the planned label expansion filing with the US FDA in 2026, which could broaden the patient base for the drug. Regulatory review is expected in 2027 if the submission is accepted. Technically, SNY stock remains near its session high of $43.48.